{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T15:00:43Z","timestamp":1769094043624,"version":"3.49.0"},"reference-count":57,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T00:00:00Z","timestamp":1762473600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T00:00:00Z","timestamp":1762473600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neuropsychopharmacol."],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1038\/s41386-025-02275-0","type":"journal-article","created":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T09:35:15Z","timestamp":1762508115000},"page":"682-690","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Associations of neuromelanin in the substantia nigra with antipsychotic response in schizophrenia"],"prefix":"10.1038","volume":"51","author":[{"given":"Ryosuke","family":"Tarumi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shiori","family":"Honda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Clifford","family":"Cassidy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takahide","family":"Etani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Saki","family":"Homma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shunya","family":"Sekihara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuka","family":"Kaneko","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sotaro","family":"Moriyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yui","family":"Tobari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koki","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3463-5672","authenticated-orcid":false,"given":"Fumihiko","family":"Ueno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guillermo","family":"Horga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9974-316X","authenticated-orcid":false,"given":"Sakiko","family":"Tsugawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0056-4135","authenticated-orcid":false,"given":"Jose M.","family":"Rubio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mie","family":"Matsui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shinya","family":"Fujii","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ariel","family":"Graff-Guerrero","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2155-0357","authenticated-orcid":false,"given":"Yoshihiro","family":"Noda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0628-7036","authenticated-orcid":false,"given":"Hiroyuki","family":"Uchida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2601-2195","authenticated-orcid":false,"given":"Shinichiro","family":"Nakajima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,11,7]]},"reference":[{"key":"2275_CR1","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1097\/YIC.0b013e32836508e6","volume":"29","author":"JL Kennedy","year":"2014","unstructured":"Kennedy JL, Altar CA, Taylor DL, Degtiar I, Hornberger JC. The social and economic burden of treatment-resistant schizophrenia: a systematic literature review. Int Clin Psychopharmacol. 2014;29:63\u201376.","journal-title":"Int Clin Psychopharmacol"},{"key":"2275_CR2","doi-asserted-by":"publisher","first-page":"2950","DOI":"10.1038\/s41380-022-01572-0","volume":"27","author":"M Wada","year":"2022","unstructured":"Wada M, Noda Y, Iwata Y, Tsugawa S, Yoshida K, Tani H, et al. Dopaminergic dysfunction and excitatory\/inhibitory imbalance in treatment-resistant schizophrenia and novel neuromodulatory treatment. Mol Psychiatry. 2022;27:2950\u201367.","journal-title":"Mol Psychiatry"},{"key":"2275_CR3","doi-asserted-by":"publisher","first-page":"8104","DOI":"10.1073\/pnas.97.14.8104","volume":"97","author":"A Abi-Dargham","year":"2000","unstructured":"Abi-Dargham A, Rodenhiser J, Printz D, Zea-Ponce Y, Gil R, Kegeles LS, et al. Increased baseline occupancy of D2 receptors by dopamine in schizophrenia. Proc Natl Acad Sci USA. 2000;97:8104\u20139.","journal-title":"Proc Natl Acad Sci USA"},{"key":"2275_CR4","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.cca.2015.03.020","volume":"449","author":"F Caravaggio","year":"2015","unstructured":"Caravaggio F, Borlido C, Wilson A, Graff-Guerrero A. Examining endogenous dopamine in treated schizophrenia using [11C]-(+)-PHNO positron emission tomography: A pilot study. Clin Chim Acta. 2015;449:60\u20132.","journal-title":"Clin Chim Acta"},{"key":"2275_CR5","doi-asserted-by":"publisher","first-page":"s13","DOI":"10.1192\/bjp.191.51.s13","volume":"51","author":"OD Howes","year":"2007","unstructured":"Howes OD, Montgomery AJ, Asselin M-C, Murray RM, Grasby PM, McGuire PK. Molecular imaging studies of the striatal dopaminergic system in psychosis and predictions for the prodromal phase of psychosis. Br J Psychiatry. 2007;51:s13\u20138.","journal-title":"Br J Psychiatry"},{"key":"2275_CR6","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1093\/schbul\/sbx180","volume":"44","author":"R McCutcheon","year":"2018","unstructured":"McCutcheon R, Beck K, Jauhar S, Howes OD. Defining the locus of dopaminergic dysfunction in schizophrenia: A meta-analysis and test of the mesolimbic hypothesis. Schizophr Bull. 2018;44:1301\u201311.","journal-title":"Schizophr Bull"},{"key":"2275_CR7","doi-asserted-by":"publisher","first-page":"1502","DOI":"10.1038\/s41380-018-0042-4","volume":"24","author":"S Jauhar","year":"2019","unstructured":"Jauhar S, Veronese M, Nour MM, Rogdaki M, Hathway P, Turkheimer FE, et al. Determinants of treatment response in first-episode psychosis: an 18F-DOPA PET study. Mol Psychiatry. 2019;24:1502\u201312.","journal-title":"Mol Psychiatry"},{"key":"2275_CR8","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1038\/npp.2016.258","volume":"42","author":"E Kim","year":"2017","unstructured":"Kim E, Howes OD, Veronese M, Beck K, Seo S, Park JW, et al. Presynaptic dopamine capacity in patients with treatment-resistant schizophrenia taking clozapine: An [18F]DOPA PET study. Neuropsychopharmacology. 2017;42:941\u201350.","journal-title":"Neuropsychopharmacology"},{"key":"2275_CR9","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1176\/appi.ajp.2012.12010144","volume":"169","author":"A Demjaha","year":"2012","unstructured":"Demjaha A, Murray RM, McGuire PK, Kapur S, Howes OD. Dopamine synthesis capacity in patients with treatment-resistant schizophrenia. Am J Psychiatry. 2012;169:1203\u201310.","journal-title":"Am J Psychiatry"},{"key":"2275_CR10","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1093\/schbul\/sbaa128","volume":"47","author":"A Egerton","year":"2020","unstructured":"Egerton A, Murphy A, Donocik J, Anton A, Barker GJ, Collier T, et al. Dopamine and Glutamate in Antipsychotic-Responsive Compared With Antipsychotic-Nonresponsive Psychosis: A Multicenter Positron Emission Tomography and Magnetic Resonance Spectroscopy Study (STRATA). Schizophr Bull. 2020;47:505\u201316.","journal-title":"Schizophr Bull"},{"key":"2275_CR11","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.1093\/brain\/awz093","volume":"142","author":"M Avram","year":"2019","unstructured":"Avram M, Brandl F, Cabello J, Leucht C, Scherr M, Mustafa M, et al. Reduced striatal dopamine synthesis capacity in patients with schizophrenia during remission of positive symptoms. Brain. 2019;142:1813\u201326.","journal-title":"Brain"},{"key":"2275_CR12","doi-asserted-by":"publisher","first-page":"e11","DOI":"10.1016\/j.biopsych.2013.06.011","volume":"75","author":"A Demjaha","year":"2014","unstructured":"Demjaha A, Egerton A, Murray RM, Kapur S, Howes OD, Stone JM, et al. Antipsychotic treatment resistance in schizophrenia associated with elevated glutamate levels but normal dopamine function. Biol Psychiatry. 2014;75:e11\u20133.","journal-title":"Biol Psychiatry"},{"key":"2275_CR13","doi-asserted-by":"publisher","first-page":"5108","DOI":"10.1073\/pnas.1807983116","volume":"116","author":"CM Cassidy","year":"2019","unstructured":"Cassidy CM, Zucca FA, Girgis RR, Baker SC, Weinstein JJ, Sharp ME, et al. Neuromelanin-sensitive MRI as a noninvasive proxy measure of dopamine function in the human brain. Proc Natl Acad Sci. 2019;116:5108\u201317.","journal-title":"Proc Natl Acad Sci"},{"key":"2275_CR14","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1016\/j.neubiorev.2021.10.028","volume":"132","author":"F Ueno","year":"2022","unstructured":"Ueno F, Iwata Y, Nakajima S, Caravaggio F, Rubio JM, Horga G, et al. Neuromelanin accumulation in patients with schizophrenia: A systematic review and meta-analysis. Neurosci Biobehav Rev. 2022;132:1205\u201313.","journal-title":"Neurosci Biobehav Rev"},{"key":"2275_CR15","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1176\/appi.ajp.20220780","volume":"181","author":"M van der Pluijm","year":"2024","unstructured":"van der Pluijm M, Wengler K, Reijers PN, Cassidy CM, Tjong Tjin Joe K, de Peuter OR, et al. Neuromelanin-Sensitive MRI as Candidate Marker for Treatment Resistance in First-Episode Schizophrenia. Am J Psychiatry. 2024;181:512\u20139.","journal-title":"Am J Psychiatry"},{"key":"2275_CR16","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1001\/jamapsychiatry.2023.4305","volume":"81","author":"K Wengler","year":"2024","unstructured":"Wengler K, Baker SC, Velikovskaya A, Fogelson A, Girgis RR, Reyes-Madrigal F, et al. Generalizability and out-of-sample predictive ability of associations between neuromelanin-sensitive magnetic resonance imaging and psychosis in antipsychotic-free individuals. JAMA Psychiatry. 2024;81:198\u2013208.","journal-title":"JAMA Psychiatry"},{"key":"2275_CR17","doi-asserted-by":"publisher","first-page":"542","DOI":"10.3389\/fnins.2020.00542","volume":"14","author":"K-A Conn","year":"2020","unstructured":"Conn K-A, Burne THJ, Kesby JP. Subcortical dopamine and cognition in schizophrenia: Looking beyond psychosis in preclinical models. Front Neurosci. 2020;14:542.","journal-title":"Front Neurosci"},{"key":"2275_CR18","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1001\/jamapsychiatry.2014.2414","volume":"72","author":"M Slifstein","year":"2015","unstructured":"Slifstein M, van de Giessen E, Van Snellenberg J, Thompson JL, Narendran R, Gil R, et al. Deficits in prefrontal cortical and extrastriatal dopamine release in schizophrenia: a positron emission tomographic functional magnetic resonance imaging study. JAMA Psychiatry. 2015;72:316\u201324.","journal-title":"JAMA Psychiatry"},{"key":"2275_CR19","first-page":"61","volume":"51","author":"G Arbanas","year":"2015","unstructured":"Arbanas G. Diagnostic and statistical manual of mental disorders (DSM-5). Alcoholism Psychiatry Res. 2015;51:61\u20134.","journal-title":"Alcoholism Psychiatry Res"},{"key":"2275_CR20","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1176\/appi.ajp.2016.16050503","volume":"174","author":"OD Howes","year":"2017","unstructured":"Howes OD, McCutcheon R, Agid O, de Bartolomeis A, van Beveren NJM, Birnbaum ML, et al. Treatment-Resistant Schizophrenia: Treatment Response and Resistance in Psychosis (TRRIP) Working Group Consensus Guidelines on Diagnosis and Terminology. Am J Psychiatry. 2017;174:216\u201329.","journal-title":"Am J Psychiatry"},{"key":"2275_CR21","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1016\/j.biopsych.2018.09.009","volume":"85","author":"Y Iwata","year":"2019","unstructured":"Iwata Y, Nakajima S, Plitman E, Caravaggio F, Kim J, Shah P, et al. Glutamatergic Neurometabolite Levels in Patients With Ultra-Treatment-Resistant Schizophrenia: A Cross-Sectional 3T Proton Magnetic Resonance Spectroscopy Study. Biol Psychiatry. 2019;85:596\u2013605.","journal-title":"Biol Psychiatry"},{"key":"2275_CR22","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1176\/appi.ajp.162.3.441","volume":"162","author":"NC Andreasen","year":"2005","unstructured":"Andreasen NC, Carpenter WT Jr, Kane JM, Lasser RA, Marder SR, Weinberger DR. Remission in schizophrenia: proposed criteria and rationale for consensus. Am J Psychiatry. 2005;162:441\u20139.","journal-title":"Am J Psychiatry"},{"key":"2275_CR23","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1093\/schbul\/13.2.261","volume":"13","author":"SR Kay","year":"1987","unstructured":"Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull. 1987;13:261\u201376.","journal-title":"Schizophr Bull"},{"key":"2275_CR24","unstructured":"Guy W ECDEU assessment manual for psychopharmacology. U.S. Department of Health, Education, and Welfare, Public Health Service, Alcohol, Drug Abuse, and Mental Health Administration, National Institute of Mental Health, Psychopharmacology Research Branch, Division of Extramural Research Programs; 1976."},{"key":"2275_CR25","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1192\/bjp.166.5.654","volume":"166","author":"SH Jones","year":"1995","unstructured":"Jones SH, Thornicroft G, Coffey M, Dunn G. A brief mental health outcome scale-reliability and validity of the Global Assessment of Functioning (GAF). Br J Psychiatry. 1995;166:654\u20139.","journal-title":"Br J Psychiatry"},{"key":"2275_CR26","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1076\/jcen.20.3.310.823","volume":"20","author":"C Randolph","year":"1998","unstructured":"Randolph C, Tierney MC, Mohr E, Chase TN. The Repeatable Battery for the Assessment of Neuropsychological Status (RBANS): preliminary clinical validity. J Clin Exp Neuropsychol. 1998;20:310\u20139.","journal-title":"J Clin Exp Neuropsychol"},{"key":"2275_CR27","first-page":"31","volume":"21","author":"M Matsui","year":"2010","unstructured":"Matsui M, Kasai Y, Nagasaki M. Reliability and validity for the Japanese version of the repeatable battery for the assessment of neuropsychological status (RBANS). Toyama Med J. 2010;21:31\u20136.","journal-title":"Toyama Med J"},{"key":"2275_CR28","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1111\/j.1532-5415.1992.tb03646.x","volume":"40","author":"DR Royall","year":"1992","unstructured":"Royall DR, Mahurin RK, Gray KF. Bedside assessment of executive cognitive impairment: the executive interview. J Am Geriatr Soc. 1992;40:1221\u20136.","journal-title":"J Am Geriatr Soc"},{"key":"2275_CR29","doi-asserted-by":"publisher","first-page":"1387","DOI":"10.1017\/S104161021400088X","volume":"26","author":"T Matsuoka","year":"2014","unstructured":"Matsuoka T, Kato Y, Taniguchi S, Ogawa M, Fujimoto H, Okamura A, et al. Japanese versions of the executive interview (J-EXIT25) and the executive clock drawing task (J-CLOX) for older people. Int Psychogeriatr. 2014;26:1387\u201397.","journal-title":"Int Psychogeriatr"},{"key":"2275_CR30","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1111\/j.1440-1819.2006.01510.x","volume":"60","author":"K Matsuoka","year":"2006","unstructured":"Matsuoka K, Uno M, Kasai K, Koyama K, Kim Y. Estimation of premorbid IQ in individuals with Alzheimer\u2019s disease using Japanese ideographic script (Kanji) compound words: Japanese version of National Adult Reading Test. Psychiatry Clin Neurosci. 2006;60:332\u20139.","journal-title":"Psychiatry Clin Neurosci"},{"key":"2275_CR31","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.media.2007.06.004","volume":"12","author":"BB Avants","year":"2008","unstructured":"Avants BB, Epstein CL, Grossman M, Gee JC. Symmetric diffeomorphic image registration with cross-correlation: evaluating automated labeling of elderly and neurodegenerative brain. Med Image Anal. 2008;12:26\u201341.","journal-title":"Med Image Anal"},{"key":"2275_CR32","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuroimage.2019.116457","volume":"208","author":"K Wengler","year":"2020","unstructured":"Wengler K, He X, Abi-Dargham A, Horga G. Reproducibility assessment of neuromelanin-sensitive magnetic resonance imaging protocols for region-of-interest and voxelwise analyses. Neuroimage. 2020;208:116457.","journal-title":"Neuroimage"},{"key":"2275_CR33","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1016\/S0014-5793(01)03269-0","volume":"510","author":"L Zecca","year":"2002","unstructured":"Zecca L, Fariello R, Riederer P, Sulzer D, Gatti A, Tampellini D. The absolute concentration of nigral neuromelanin, assayed by a new sensitive method, increases throughout the life and is dramatically decreased in Parkinson\u2019s disease. FEBS Lett. 2002;510:216\u201320.","journal-title":"FEBS Lett"},{"key":"2275_CR34","doi-asserted-by":"publisher","first-page":"e2457868","DOI":"10.1001\/jamanetworkopen.2024.57868","volume":"8","author":"DT Myran","year":"2025","unstructured":"Myran DT, Pugliese M, Harrison LD, Solmi M, Anderson KK, Fiedorowicz JG, et al. Changes in incident schizophrenia diagnoses associated with cannabis use disorder after cannabis legalization. JAMA Netw Open. 2025;8:e2457868.","journal-title":"JAMA Netw Open"},{"key":"2275_CR35","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1038\/nature20153","volume":"539","author":"MAP Bloomfield","year":"2016","unstructured":"Bloomfield MAP, Ashok AH, Volkow ND, Howes OD. The effects of \u03949-tetrahydrocannabinol on the dopamine system. Nature. 2016;539:369\u201377.","journal-title":"Nature"},{"key":"2275_CR36","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1001\/jamapsychiatry.2025.0432","volume":"82","author":"J Ahrens","year":"2025","unstructured":"Ahrens J, Ford SD, Schaefer B, Reese D, Khan AR, Tibbo P, et al. Convergence of cannabis and psychosis on the dopamine system. JAMA Psychiatry. 2025;82:609\u201317.","journal-title":"JAMA Psychiatry"},{"key":"2275_CR37","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1176\/appi.ajp.20220819","volume":"181","author":"G Perlman","year":"2024","unstructured":"Perlman G, Wengler K, Moeller SJ, Kotov R, Klein DN, Weinstein JJ, et al. Association of neuromelanin-sensitive MRI signal with lifetime substance use in young women. Am J Psychiatry. 2024;181:997\u20131005.","journal-title":"Am J Psychiatry"},{"key":"2275_CR38","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1038\/s41531-018-0050-8","volume":"4","author":"FA Zucca","year":"2018","unstructured":"Zucca FA, Vanna R, Cupaioli FA, Bellei C, De Palma A, Di Silvestre D, et al. Neuromelanin organelles are specialized autolysosomes that accumulate undegraded proteins and lipids in aging human brain and are likely involved in Parkinson\u2019s disease. NPJ Parkinsons Dis. 2018;4:17.","journal-title":"NPJ Parkinsons Dis"},{"key":"2275_CR39","first-page":"359","volume":"103","author":"DG Graham","year":"1979","unstructured":"Graham DG. On the origin and significance of neuromelanin. Arch Pathol Lab Med. 1979;103:359\u201362.","journal-title":"Arch Pathol Lab Med"},{"key":"2275_CR40","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1177\/1073858409338217","volume":"15","author":"Y Kumakura","year":"2009","unstructured":"Kumakura Y, Cumming P. PET studies of cerebral levodopa metabolism: a review of clinical findings and modeling approaches. Neuroscientist. 2009;15:635\u201350.","journal-title":"Neuroscientist"},{"key":"2275_CR41","doi-asserted-by":"crossref","unstructured":"Vano LJ, McCutcheon RA, Rutigliano G, Kaar SJ, Finelli V, Nordio G, et al. Mesostriatal Dopaminergic Circuit Dysfunction in Schizophrenia: A Multimodal Neuromelanin-sensitive MRI and [18F]-DOPA PET Study. Biol Psychiatry. 2024;96:674\u2013683.","DOI":"10.1016\/j.biopsych.2024.06.013"},{"key":"2275_CR42","doi-asserted-by":"publisher","DOI":"10.1016\/j.nsa.2023.101134","volume":"2","author":"CFM van Hooijdonk","year":"2023","unstructured":"van Hooijdonk CFM, van der Pluijm M, Smith C, Yaqub M, van Velden FHP, Horga G, et al. Striatal dopamine synthesis capacity and neuromelanin in the substantia nigra: A multimodal imaging study in schizophrenia and healthy controls. Neuroscience Appl. 2023;2:101134.","journal-title":"Neuroscience Appl"},{"key":"2275_CR43","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1093\/schbul\/sbt043","volume":"39","author":"DV Jeste","year":"2013","unstructured":"Jeste DV, Maglione JE. Treating older adults with schizophrenia: challenges and opportunities. Schizophr Bull. 2013;39:966\u20138.","journal-title":"Schizophr Bull"},{"key":"2275_CR44","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1093\/schbul\/sbr026","volume":"37","author":"DV Jeste","year":"2011","unstructured":"Jeste DV, Wolkowitz OM, Palmer BW. Divergent trajectories of physical, cognitive, and psychosocial aging in schizophrenia. Schizophr Bull. 2011;37:451\u20135.","journal-title":"Schizophr Bull"},{"key":"2275_CR45","first-page":"212","volume":"42","author":"S Nakajima","year":"2016","unstructured":"Nakajima S, Uchida H, Bies RR, Caravaggio F, Suzuki T, Plitman E, et al. Dopamine D2\/3 receptor occupancy following dose reduction is predictable with minimal plasma antipsychotic concentrations: An open-label clinical trial. Schizophr Bull. 2016;42:212\u20139.","journal-title":"Schizophr Bull"},{"key":"2275_CR46","doi-asserted-by":"publisher","first-page":"1812","DOI":"10.1038\/jcbfm.2015.129","volume":"35","author":"S Nakajima","year":"2015","unstructured":"Nakajima S, Caravaggio F, Boileau I, Chung JK, Plitman E, Gerretsen P, et al. Lack of age-dependent decrease in dopamine D3 receptor availability: a [(11)C]-(+)-PHNO and [(11)C]-raclopride positron emission tomography study. J Cereb Blood Flow Metab. 2015;35:1812\u20138.","journal-title":"J Cereb Blood Flow Metab"},{"key":"2275_CR47","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1001\/jamapsychiatry.2015.0891","volume":"72","author":"A Graff-Guerrero","year":"2015","unstructured":"Graff-Guerrero A, Rajji TK, Mulsant BH, Nakajima S, Caravaggio F, Suzuki T, et al. Evaluation of antipsychotic dose reduction in late-life schizophrenia: A prospective dopamine D2\/3 receptor occupancy study: A prospective dopamine D2\/3Receptor occupancy study. JAMA Psychiatry. 2015;72:927\u201334.","journal-title":"JAMA Psychiatry"},{"key":"2275_CR48","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1093\/schbul\/sbae111","volume":"51","author":"A Weidenauer","year":"2024","unstructured":"Weidenauer A, Sauerzopf U, Bauer M, Bum C, Diendorfer C, Dajic I, et al. Amphetamine-induced dopamine release predicts 1-year outcome in first-episode psychosis: A naturalistic observation. Schizophr Bull. 2024;51:159\u201369.","journal-title":"Schizophr Bull"},{"key":"2275_CR49","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1016\/j.biopsych.2021.08.023","volume":"91","author":"AK Sigvard","year":"2022","unstructured":"Sigvard AK, Nielsen M\u00d8, Gjedde A, Bojesen KB, Fugl\u00f8 D, Tangmose K, et al. Dopaminergic activity in antipsychotic-na\u00efve patients assessed with positron emission tomography before and after partial dopamine D2 receptor agonist treatment: Association with psychotic symptoms and treatment response. Biol Psychiatry. 2022;91:236\u201345.","journal-title":"Biol Psychiatry"},{"key":"2275_CR50","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/j.biopsych.2019.07.008","volume":"87","author":"SP Brugger","year":"2020","unstructured":"Brugger SP, Angelescu I, Abi-Dargham A, Mizrahi R, Shahrezaei V, Howes OD. Heterogeneity of Striatal Dopamine Function in Schizophrenia: Meta-analysis of Variance. Biol Psychiatry. 2020;87:215\u201324.","journal-title":"Biol Psychiatry"},{"key":"2275_CR51","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1016\/j.neuroscience.2014.10.008","volume":"282","author":"SN Haber","year":"2014","unstructured":"Haber SN. The place of dopamine in the cortico-basal ganglia circuit. Neuroscience. 2014;282:248\u201357.","journal-title":"Neuroscience"},{"key":"2275_CR52","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1523\/JNEUROSCI.4029-08.2009","volume":"29","author":"W Matsuda","year":"2009","unstructured":"Matsuda W, Furuta T, Nakamura KC, Hioki H, Fujiyama F, Arai R, et al. Single nigrostriatal dopaminergic neurons form widely spread and highly dense axonal arborizations in the neostriatum. J Neurosci. 2009;29:444\u201353.","journal-title":"J Neurosci"},{"key":"2275_CR53","doi-asserted-by":"crossref","unstructured":"Prensa L, Gim\u00e9nez-Amaya JM, Parent A, Bern\u00e1cer J, Cebri\u00e1n C The nigrostriatal pathway: axonal collateralization and compartmental specificity. J Neural Transm Suppl. 2009;73:49\u201358.","DOI":"10.1007\/978-3-211-92660-4_4"},{"key":"2275_CR54","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1016\/j.euroneuro.2013.05.006","volume":"23","author":"S Nakajima","year":"2013","unstructured":"Nakajima S, Gerretsen P, Takeuchi H, Caravaggio F, Chow T, Le Foll B, et al. The potential role of dopamine D\u2083 receptor neurotransmission in cognition. Eur Neuropsychopharmacol. 2013;23:799\u2013813.","journal-title":"Eur Neuropsychopharmacol"},{"key":"2275_CR55","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1038\/s41531-024-00631-3","volume":"10","author":"DA Lakhani","year":"2024","unstructured":"Lakhani DA, Zhou X, Tao S, Patel V, Wen S, Okromelidze L, et al. Diagnostic utility of 7T neuromelanin imaging of the substantia nigra in Parkinson\u2019s disease. NPJ Parkinsons Dis. 2024;10:13.","journal-title":"NPJ Parkinsons Dis"},{"key":"2275_CR56","doi-asserted-by":"publisher","DOI":"10.1016\/j.pneurobio.2022.102265","volume":"213","author":"CFM van Hooijdonk","year":"2022","unstructured":"van Hooijdonk CFM, Drukker M, van de Giessen E, Booij J, Selten J-P, van Amelsvoort TAMJ. Dopaminergic alterations in populations at increased risk for psychosis: A systematic review of imaging findings. Prog Neurobiol. 2022;213:102265.","journal-title":"Prog Neurobiol"},{"key":"2275_CR57","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/j.biopsych.2007.04.017","volume":"63","author":"J Huttunen","year":"2008","unstructured":"Huttunen J, Heinimaa M, Svirskis T, Nyman M, Kajander J, Forsback S, et al. Striatal dopamine synthesis in first-degree relatives of patients with schizophrenia. Biol Psychiatry. 2008;63:114\u20137.","journal-title":"Biol Psychiatry"}],"container-title":["Neuropsychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41386-025-02275-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41386-025-02275-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41386-025-02275-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T23:03:20Z","timestamp":1769036600000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41386-025-02275-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,7]]},"references-count":57,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["2275"],"URL":"https:\/\/doi.org\/10.1038\/s41386-025-02275-0","relation":{},"ISSN":["0893-133X","1740-634X"],"issn-type":[{"value":"0893-133X","type":"print"},{"value":"1740-634X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,7]]},"assertion":[{"value":"7 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 October 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 October 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 November 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors have nothing to disclose.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}